Exercise bouts could improve efficacy of cancer drug, claims study Dr. Kamal Kant Kohli24 May 2024 10:00 PM ISTBouts of moderate-to-vigorous intensity exercise could improve the efficacy of antibody therapies used to treat chronic lymphocytic leukaemia, new...
AstraZeneca Calquence tablet formulation approved in EU for adults with chronic lymphocytic leukaemia Ruchika Sharma23 Feb 2023 11:30 AM ISTCalquence (acalabrutinib) is a next-generation, selective inhibitor of Bruton's tyrosine kinase (BTK).
Dr Reddy's labs completes clinical studies of Rituximab biosimilar for filing in US, Europe Ruchika Sharma20 Jan 2023 3:30 PM ISTWith the successful completion of these clinical studies, Dr. Reddy’s is now preparing to file Biologics License Application (BLA) / Marketing...
AstraZeneca Calquence gets Japenese nod for treatment-naïve chronic lymphocytic leukaemia Ruchika Sharma1 Jan 2023 10:00 AM ISTCalquence (acalabrutinib) is a next-generation, selective inhibitor of BTK.
AstraZeneca new tablet formulation of Calquence gets USFDA okay Ruchika Sharma8 Aug 2022 12:30 PM IST"The tablet can be taken with gastric acid-reducing agents, including proton pump inhibitors (PPIs), antacids and H2-receptor antagonists (H2RAs),"...
Acalabrutinib, venetoclax and obinutuzumab as frontline therapy for chronic lymphocytic leukemia: Lancet MD Editorial Team24 Sept 2021 9:00 PM ISTUSA: In a trial led by Matthew S Davids, individuals with undiscovered minimum residual disease (MRD) and untreated chronic lymphocytic leukemia who...
